EGFR and non-small cell lung carcinoma: This has led to efforts to clinically target crosstalk between Met and EGFR itself, but despite combinatorial inhibition of Met and EGFR showing improved efficacy in cell culture and xenograft mouse models of non-small-cell lung cancer with MET amplification and EGFR mutations [22–25], this benefit was not supported in clinical trials [23].